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Summary 
 
Aim.  To produce a clinical protocol for pulp therapy techniques in the extensively 
carious primary molar. 
 
Introduction.  The International Agency for Research on Cancer (IARC) has recently 
classified formaldehyde as carcinogenic to humans.  As such, a medicament that can 
be used to replace formocresol in clinical practice should be identified. 
 
Method.   Part I of this paper explored the currently available alternative interventions 
and materials to formocresol in the form of a narrative review following an extensive 
literature search.  Part II now presents the formation of a specialist group to establish 
an evidence-based protocol, for the management of the extensively carious primary 
molar.  
 
Conclusion.  A protocol and key points document have been developed to assist 
clinicians in their treatment planning.  Areas for further post-graduate training have 
been identified. 
 
Aim 
 
To produce a working clinical protocol for pulp therapy techniques in the extensively 
carious primary molar. 
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Introduction 
 
Buckley’s Formocresol was first introduced as a pulp medicament in 1904 [1] and 
since 1930 [2] has been the treatment of choice for primary molar vital pulpotomies.   
There is much published work relating to its clinical use with clinical success ranging 
from 55% to 98%. [3, 4, 5, 6, 7, 8]  Several studies in the 1970’s demonstrated that a 
one-fifth dilution of formocresol was as effective as a full strength solution in terms of 
initial cytotoxicity to fibroblasts [9, 10, 11, 12].  Concern over the use of 
formaldehyde has been voiced for some time [13 (cited in [17]), 14, 15, 16, 17] but 
until recently the evidence has been equivocal.   
 
Animal studies 
 
Formaldehyde has been shown to be mutagenic in Escherichia coli bacteria [18,19] 
and the fruit fly Drosophila [20].  When administered in drinking water, formaldehyde 
produced an increase in total malignant tumours in rats [21] and when inhaled has 
been shown to induce squamous cell carcinoma of the nasal cavity [22].  Long-term 
studies using rabbits have demonstrated that prolonged contact with formaldehyde 
may produce precancerous and cancerous states in the epithelium [23].  Other authors 
have suggested caution in extrapolating the findings of animal studies to humans.  In 
particular the rat has been shown to be more susceptible to changes induced by 
inhaled formaldehyde [24]. 
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Human in vitro studies 
 
Mammalian cell in vitro studies have demonstrated unscheduled DNA synthesis in 
HeLa cells as a result of formaldehyde application [25] and increased cell 
proliferation in respiratory mucosa [22].  Forward mutations have also been produced 
by formaldehyde in a human lymphoblastoid cell line [26].  Experimental evidence 
suggests that inhaled formaldehyde vapour can exert toxic effects at remote sites as 
well as in the respiratory tract.  Chromosomal aberrations [27, 28], increased 
micronuclei [27, 29, 30], DNA-protein cross-links [31, 32] and sister chromatid 
exchanges [27, 32, 33, 34] have been found in peripheral lymphocytes of humans 
exposed to formaldehyde.  Although there is an established link between 
chromosomal aberrations and cancer [35], the relationships between micronuclei or 
sister chromatid exchanges and health risks are less clear [36]. 
 
Human cohort studies 
 
Long-term cohort studies of industrial workers have found increased risks for 
leukaemia, particularly myeloid leukaemia, in medical workers and other 
professionals exposed to formaldehyde [37, 38] whilst other research does not support 
these findings [39].  Possible associations have also been suggested between 
occupational formaldehyde and cancer of the lung [39, 40], nasopharynx [39, 41], 
stomach [39], paranasal sinuses [42, 43], prostate [41, 44], brain [44] and pancreas 
[45].  However, these associations remain inconsistent.   
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Dental studies 
 
Sytemic distribution of radio-isotope labelled formaldehyde has been demonstrated 
following formocresol pulpotomy in dogs [46] and Rhesus monkeys [47].  Labelled 
formaldehyde has been found in periodontal ligament, bone, dentine and urine and 
smaller amounts in liver, kidney, lungs, skeletal muscle and cerebro-spinal fluid 
within minutes of the pulpotomy [46].  More recently a human case control study 
demonstrated a single case of mutagenicity in peripheral blood lymphocyte cultures 
following formocresol pulpotomy [48].  A correlation between formocresol 
pulpotomies in primary teeth and enamel defects in the permanent successor has been 
suggested [49] although other workers found no such links [50]. 
 
In June 2004, the IARC classified formaldehyde as carcinogenic to humans [51].  The 
expert working group determined that there is now sufficient evidence that 
formaldehyde causes nasopharyngeal cancer in humans, limited evidence for cancer 
of the nasal cavity and paranasal sinuses and strong but not sufficient evidence for a 
causal association between leukaemia and occupational exposure to formaldehyde.  
The IARC working group recommended further research in order to identify a 
mechanism for the induction of leukaemia and to build on the existing evidence base. 
 
Care pathways, clinical protocols and decision trees 
 
The National Pathway Association was founded in 1994 to support the development 
of integrated care pathways.  A care pathway determines locally agreed, 
multidisciplinary practice based on guidelines and evidence where available, for a 
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specific patient group.  It forms all, or part of, the clinical record, documents the care 
given and facilitates the evaluation of outcomes for continuous quality improvement 
[52].   
 
A clinical protocol is a written framework for the expected management path and 
outcome for a patient undergoing a particular procedure.  Clinical protocols and care 
pathways are being widely implemented in the National Health Service (NHS), and 
although initially concerns were expressed regarding the lack of evidence for their 
efficacy [53, 54], recent work has helped to address this issue.  It would appear that 
both are capable of improving quality of care and patient satisfaction [55].  The aim of 
a clinical protocol is to improve the quality of care and ensure that treatment is based 
on the latest evidence and research.  They should complement rather than abolish 
intuitive thought based on clinical expertise.  Education and training strategies are 
essential to support understanding, ownership and acceptance [56]. 
 
Decision analysis is the application of structured, quantitative methods to analyse 
decisions under conditions of uncertainty [57].  They can be shown graphically as 
decision trees and help to structure problems and highlight areas for further research.  
Decision analysis works on the principle that the degree of uncertainty decreases 
when the medical literature includes directly relevant, valid evidence [58]. 
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Methods 
 
Protocol development 
 
On 15th June 2004 the IARC issued a press release classifying formaldehyde as 
carcinogenic to humans [51].  This information was circulated to all Consultants in 
Paediatric Dentistry and resulted in the withdrawal of Buckley’s formocresol and all 
paraformaldehyde containing devitalising pastes from the majority of Teaching 
Hospitals.  In the Department of Child Dental Health, Newcastle upon Tyne a 
specialist group of paediatric dentists, comprising consultants, specialist registrars, 
university academics and a staff grade, was formed in order to establish a consensus 
decision on the management of extensively carious primary molar teeth. 
 
A traditional narrative literature review was completed [Part I of this publication] and 
primary research papers for each of the possible alternatives to formocresol were 
identified.  Where possible randomised control trials were chosen to evaluate clinical 
and radiographic success for each medicament [59, 60, 61, 62, 63, 64, 65].  
Histological animal studies were identified to enable comparison between the 
cytological and toxicological effects of different medicaments and techniques [66, 
67].  Each clinician in the specialist group was asked to critically appraise their 
allocated papers and to present their findings at a ‘brainstorming’ session. 
 
Following appraisal of the selected publications, the group discussed the ideal 
properties of a pulp therapy agent and tabulated the key findings of the review [Table 
1].  It was felt that in light of the recent IARC findings, it was necessary to implement 
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the chosen alternatives as soon as possible, whilst also considering techniques that 
may be possible in the future. 
 
For inclusion in the protocol it was necessary for a technique or medicament to have a 
sufficient evidence base, ideally human trials, for clinical efficacy and to be 
economical in order to justify its routine use within an NHS teaching hospital.  There 
should also be little immediate financial outlay or training implications to allow rapid 
introduction of the protocol. 
 
On this basis, ferric sulphate (Astringedent, Ultradent Products Inc) was chosen for 
use in the vital primary molar pulpotomy.  Although concerns were expressed that this 
agent may mask underlying pulp pathosis, it was felt that it was clinically successful, 
operator and patient friendly and a financially viable medicament.  MTA (Pro Root, 
Dentsply, Tulsa Dental) will also be an option for staff-performed pulpotomies and 
perhaps introduced into the undergraduate arena in the future.  
 
A working draft of the protocol was produced and circulated to enter into the 
‘iterative’ process of review.  The draft protocol consisted of a flow chart to assist 
clinicians in their treatment planning combined with a key points document to offer 
further information and to standardise data for future research and audit.  Each draft 
version was then circulated for comment a further three times.   This resulted in the 
working protocol [Figure 1]. To facilitate future audit of the protocol, every time pulp 
therapy is performed within the Department, a stamp will be used to record 
standardised information in the patient’s notes, for example the time taken to achieve 
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haemostasis and the number of applications of ferric sulphate required.  The 
information will also be recorded in a ‘pulp therapy book’. 
 
Implementation of the protocol 
 
Undergraduate dental students were informed of changes in protocol via information 
uploaded within the University Virtual Learning Environment.  In addition, a lecture 
was given to all third year students, prior to their initial clinical sessions within 
paediatric dentistry and an existing seminar was revised to include an update on pulp 
therapy in the primary dentition.  The same information was supplied to all teachers 
of paediatric dentistry within the School and in Outreach clinics.  It is expected that 
further modifications to the teaching programme will be made as pulp therapy 
techniques are developed and audited. 
 
The working protocol and key points document were circulated to all staff working 
within the Department.  Discussion of these documents was incorporated into the 
junior staff induction programme.  Nursing staff were also informed of the new 
techniques and proposed local protocol via the senior nurse.  Areas for future staff 
training were identified at the team meeting and hands-on training for specialist staff 
has been arranged for the near future.  
 
Discussion 
 
Following the recent IARC press release [51], the use of formocresol in paediatric 
dentistry is no longer recommended and clinicians must adopt alternative evidence 
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based procedures.  The authors acknowledge that the evidence for some of the 
alternatives to formocresol is weak.  However, the IARC statement demands a change 
to current practice and an urgent review of the alternatives in order to develop an 
interim protocol.  It is hoped that this protocol will add to the debate and enable the 
collection of standardised data which will, in turn lead to a more evidence-based 
guideline in the future. 
 
The importance of careful patient and tooth selection when considering provision of a 
pulp therapy cannot be over-emphasised.  In order for vital pulp therapy to be 
successful, the patient must be sufficiently compliant to allow adequate moisture 
control, ideally with rubber dam placement, and the tooth must be radiographically 
free of pathology and restorable with a bonded restoration or pre-formed metal crown 
in order to provide an effective seal. 
 
Despite careful initial assessment, diagnosis of pulpal status may be difficult.  For 
example, once an irreversibly inflamed coronal pulp has been amputated, the health of 
the radicular pulp is assessed on an empirical basis i.e. how readily the pulp stump 
bleeds.  As yet we have no scientific clinical method of determining pulpal status 
prior to treatment, although there has been some work to investigate correlations 
between the presence of certain inflammatory mediators and clinical outcome [68, 
69]. 
 
Presently, in Newcastle the treatment of choice for non-vital primary molars may be 
extraction as there is little evidence of an alternative medicament which is as effective 
as formocresol and which exhibits minimal technique sensitivity.  Pulpectomy 
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remains an option for the future but staff training will be required before the technique 
can be introduced in the clinical setting and taught at undergraduate level.  The 
management of the partially-vital primary molar merits further research and 
discussion, as the evidence is scant for the use of Ledermix™ (Blackwell Supplies 
Ltd) in such teeth.   
 
In order to justify its use within an NHS teaching hospital, a medicament must be 
effective from a clinical and economical perspective.  MTA has been previously 
excluded in some centres on the basis of its expense but research would suggest that 
MTA does have a role to play in the treatment of carefully selected primary molar 
vital pulpotomies and that its cost is comparable to that of ferric sulphate. 
 
Ferric sulphate appears to be as effective in vital pulpotomies as formocresol and to 
date there is no evidence to suggest any adverse effects of this medicament.  As such, 
within our protocol it was chosen as the treatment of choice for vital pulpotomies.  
Further research and audit is required to build on the existing evidence base for ferric 
sulphate, in particular the authors would welcome more long-term randomised clinical 
trials.   
 
It has been suggested that the careful monitoring of primary teeth with extensive 
caries is a reasonable treatment option when combined with a thorough preventive 
regimen [70,71].  The authors suggest that monitoring may be appropriate, but only 
for patients who are unable to accept operative treatment and where the tooth is 
asymptomatic and clinically and radiographically free of pathology.  It is advisable 
that this decision is made with the consent of a fully informed parent due to the 
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potential risk of damage to the permanent successor.  Monitoring is not an option for 
patients to whom infection poses a significant risk, for example those with leukaemia 
or congenital heart defects. 
 
Radiographic review 
  
Regular radiographic monitoring of treated teeth is advocated to assist in the 
assessment of primary molar and permanent successor teeth.  A radiograph taken post 
treatment would enable detection of recurrent caries, a failing coronal restoration, 
periapical or furcal radiolucencies, internal or external root resorption, failure of 
eruption of the permanent successor tooth along its expected path and pathosis, with 
or without concomitant clinical symptoms which may damage or deflect the 
permanent tooth germ [50]. 
 
Although the literature relating to the frequency of radiographing pulpotomised teeth 
is scant, the Faculty of General Dental Practitioners [72] clearly outlines selection 
criteria for radiographic screening according to caries risk status.  These guidelines 
suggest that bitewing radiographs should be taken on a six-monthly basis for children 
identified as high-caries risk and on an annual basis for those classified as moderate 
risk.  The authors would suggest that a vertical bitewing radiograph could be taken as 
part of this radiographic review and would enable post pulp-therapy review without 
an increase in radiation dose. 
 
 13 
Conclusion 
 
Following review of the current literature, a working clinical protocol for pulp therapy 
techniques in the extensively carious primary molar has been developed.  This 
protocol has been implemented at undergraduate and postgraduate level and has 
helped to identify areas where further staff training is required.  It is expected that the 
clinical protocol will evolve as further evidence comes to light. 
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TABLE 1: COMPARISON OF ALTERNATIVES TO FORMOCRESOL FOR PULP THERAPY 
Material Clinical success (Example cited) 
Human clinical 
studies? 
Tested against 
formocresol? 
Operator ease 
of use 
Patient 
acceptability 
Cost of 
technique 
Effect upon pulp 
cell 
Glutaraldehyde 82% @ 25 months Fuks et al. 1986 √ √ + + + + + + + Devitalisation 
Electrosurgery 99.4% @ 70 months Mack and Dean 1993 Χ Χ + + + + Devitalisation 
Ferric sulphate 92% @ 4 years Ibrecevic et al. 2003 √ √ + + + + + + + Preservation 
Calcium 
hydroxide 
77.1% @ 22.5 months 
Waterhouse 2000 √ √ + + + + + + + Preservation 
MTA 
100% @ 1 year (grey) 
84.2% @ 1 year (white) 
Agamy et al 2004 
√ Χ + +  + + + + + + Preservation 
Lasers 100% @ 90 days Elliot et al 1999 √ √ + + + + + Preservation 
IPT 95% @ 2 –72 weeks Al Zayer et al 2003 √ √ + + + + + + + Remineralisation 
BMP No studies Χ Χ Unknown Unknown Unknown Remineralisation 
Collagen No studies Χ Χ Unknown Unknown Unknown Remineralisation 
Pulpectomy 91% @ 36 months Casas and Kenny 2000 √ √ + + + Extirpation 
Ledermix 79% @42 month Hansen et al 1971 √ Χ + + + + + +  + Preservation 
    
+ Poor 
+ + Fair 
+ + + Good 
+ Poor 
+ + Fair 
+ + + Good 
+ Low 
+ + Medium 
+ + + High 
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FIGURE 1: PRIMARY MOLAR PROTOCOL 
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Is patient suitable for pulpotomy? 
(Consider MH, no. of carious teeth, compliance, and  
parental support / preference) 
Is tooth restorable and without signs of  
peri-radicular pathology? 
Consent patient and warn carer that extraction may be 
required at a later date.  Ensure pre-operative 
periapical radiograph < 6/52 old available. 
Topical, LA and then caries removal until 
ADJ/peripheries clear, all soft caries removed and 
stained dentine left on cavity floor. 
Is tooth still restorable? 
Has there been a pulpal exposure? 
Unroof pulp chamber, ensure complete coronal 
amputation, irrigate with saline and apply pressure to 
pulp stumps with sterile cotton wool pledget.  Note 
whether haemostasis achieved within 2-3 mins. 
Apply 15% ferric sulphate for 15 sec. 
Has haemostasis been achieved? 
Reapply ferric sulphate for further 15 sec.  
Has haemostasis been achieved? 
Consider removal of further pulp tissue using hand 
instruments then reapply ferric sulphate for 15 sec.   
Has haemostasis been achieved? 
Will the patient tolerate further treatment this visit? 
Place Ledermix™ and 
GIC and review < 1 
month.  
 
Review with radiograph 
in 4-6 /12. Consider 
discharge to GDP and 
suggest annual 
radiograph 
Extract 
LA / RA / GA 
Indirect Pulp Therapy (GIC lining over dentine)+ 
PFMC / Bonded restoration 
Apply ZnOE and restore with 
PFMC/Bonded restoration. 
Consider extraction (LA/RA/GA) or pulpectomy 
based on patient cooperation. 
Is the tooth sensitive to instrumentation? 
Dress with Ledermix™ and  
restore temporarily with GIC.  
Review patient in 1-2/52. 
Consider monitoring if tooth is 
asymptomatic and clinically 
and radiographically free of 
pathology.  This must be in 
conjunction with a thorough 
preventive regimen. 
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LEGENDS 
 
Figure 1  
MH  Medical history  LA  Local anaesthesia 
RA  Relative analgesia  GA  General anaesthesia 
ADJ  Amelo-dentinal junction GIC  Glass ionomer cement 
ZnOE  Zinc oxide eugenol cement PFMC  Pre-formed metal crown 
GDP  General dental practitioner 
 
 
Table 1 
 
MTA  Mineral trioxide aggregate 
IPT  Indirect pulp therapy 
BMP  Bone morphogenic protein 
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